Quidel (NASDAQ: QDEL) and BIOLASE (NASDAQ:BIOL) are both small-cap advanced medical equipment & technology – nec companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.
Earnings & Valuation
This table compares Quidel and BIOLASE’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Quidel||$191.60 million||8.19||-$13.80 million||($0.16)||-288.56|
|BIOLASE||$51.81 million||0.78||-$15.37 million||($0.33)||-1.61|
Risk and Volatility
Quidel has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, BIOLASE has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500.
This is a summary of recent recommendations for Quidel and BIOLASE, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Quidel currently has a consensus price target of $50.00, indicating a potential upside of 8.30%. BIOLASE has a consensus price target of $2.50, indicating a potential upside of 371.70%. Given BIOLASE’s higher probable upside, analysts clearly believe BIOLASE is more favorable than Quidel.
This table compares Quidel and BIOLASE’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
92.7% of Quidel shares are held by institutional investors. Comparatively, 38.8% of BIOLASE shares are held by institutional investors. 22.0% of Quidel shares are held by insiders. Comparatively, 7.1% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Quidel beats BIOLASE on 10 of the 13 factors compared between the two stocks.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.